background preloader

Pharmaceutical Medicine - Pharmaceutics

Facebook Twitter

The Challenge of CMC Regulatory Compliance for Biopharmaceuticals and Other Biologics - UNSW Alma. Handbook of Stability Testing in Pharmaceutical Development : Regulations, Methodologies, and Best Practices - UNSW Alma. Dosage form design considerations. Volume 1 - UNSW Alma. Understanding the Essentialities in Establishing the Bioequivalence of Oral Inhalation Drug Products to be Marketed in the USA. Background Oral inhalation drug products (OIDPs) are combination products comprising two components, i.e., a device and the corresponding formulation, and are manufactured with ‘patient use’ being the key consideration.

Understanding the Essentialities in Establishing the Bioequivalence of Oral Inhalation Drug Products to be Marketed in the USA

The formulation is designed to be compatible with the device, as the device and formulation have to work in tandem for the intended effect of the drug to be imparted to the patient. OIDPs are generally categorized into three sections: pressurized metered dose inhalers (pMDIs or MDIs), dry powder inhalers (DPIs), and nebulizers. Area Covered As OIDPs are most convenient in the treatment of asthma and COPD, it makes these drugs all the more vital in terms of inhalational therapy. Expert Opinion. A Quantitative Study of US FDA Inspection Data for Drug Manufacturing Sites. NIIMBL Roadmaps. A72 22 en. Database Access - UNSW Library. Pharmaceutical and vaccine quality illustrated. Cmax: A term used in pharmacokinetics refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose.

Pharmaceutical and vaccine quality illustrated

Calibration: The demonstration that a particular instrument or device produces results within specified limits by comparison with those produced by a reference or traceable standard over an appropriate range of measurements. (ICH Q7) CAPA (Corrective and preventive actions) system: A system for implementing corrective actions and preventive actions resulting from the investigation of complaints, product rejections, non-conformances, recalls, deviations, audits, regulatory inspections and findings, and trends from process performance and product quality monitoring (ICH Q10). A structured approach to the investigation process should be used with the objective of determining the root cause. Design of a case-control study (Kartoglu) DrugBank. IUPHAR/BPS Guide to PHARMACOLOGY.

This website, originally created in a collaboration between The British Pharmacological Society (BPS) and the International Union of Basic and Clinical Pharmacology (IUPHAR) and now developed jointly with funding from the Wellcome Trust, is intended to become a “one-stop shop” portal to pharmacological information.

IUPHAR/BPS Guide to PHARMACOLOGY

One of the main aims is to provide a searchable database with quantitative information on drug targets and the prescription medicines and experimental drugs that act on them. In future versions we plan to add resources for education and training in pharmacological principles and techniques along with research guidelines and overviews of key topics. We hope that the IUPHAR/BPS Guide to PHARMACOLOGY will be useful for researchers and students in pharmacology and drug discovery and provide the general public with accurate information on the basic science underlying drug action. Click here to access the database For information on how to cite the data please visit this page.

Database Access - UNSW Library. Early Biosimilar Development: A Model for Expeditious Progress to a Phase 3 Trial. Posted 01 March 2016 By Raymond Huml, MS, DVM, RAC, Nigel Rulewski, MD, Kamali Chance, MPH, PhD, RAC, Doris Weilert, PhD, J.

Early Biosimilar Development: A Model for Expeditious Progress to a Phase 3 Trial

Rick Turner, PhD This article discusses biosimilar clinical development and how companies are addressing the clinical development concerns associated with early biosimilar drug development. Share this article: Categories: Biologics and biotechnology, Clinical, Preclinical, Regulatory strategy, Features, US, Europe, FDA, EMA, EC. Combating Counterfeit Medicines: Legal Frameworks and Emerging Technologies. Posted 18 May 2016 By Bernard D.

Combating Counterfeit Medicines: Legal Frameworks and Emerging Technologies

Naughton, Sue Dopson, Stephen R. Chapman, David A. Brindley. Regulatory One: Regulatory Agencies- Websites. North American Regulatory Agencies Health Canada, Canada European Regulatory Agencies EMA, Europe EDQM, Europe AFSSAPS, France BfArM, Germany AGES, Austria FAMHP, Belgium NCDC, Albania.

Regulatory One: Regulatory Agencies- Websites

Laetus Track and Trace Pha. Database Access - UNSW Library. Database Access - UNSW Library. Database Access - UNSW Library. Database Access - UNSW Library. Fermentation and Biochemical Engineering Handbook - Principles, Process Design, and Equipment (3rd Edition) - Knovel. Strategies to Modify the Drug Release from Pharmaceutical Systems - Knovel.

Database Access - UNSW Library. Database Access - UNSW Library. B-Com Web. Isotron Ethylene Oxide (ETO) Sterilisation. WHO Model List of Essential Medicines. 8946395. INN and Biologicals. Bq_innproposal201407.pdf. The Challenges in Manufacturing Biologics. Monoclonal Antibody Production [HD Animation] Monoclonal Antibody Production. The Making of Protein Therapies. Quality use of blood products - Australian Prescriber. Big Data in Pharma. Nbt.3036.pdf. Quality by design for biopharmaceuticals : Article : Nature Biotechnology. Www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM304305.pdf. PQLI<sup>®</sup> Part 2: Product Realization using QbD, Illustrative Example.

American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology. Pfizer Abstract The concepts described in ICH Q8-Q11, commonly referred to as Quality by Design (QbD), have also been applied to the development of analytical methods.

American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology

An overview of these concepts using the development of a reversed-phase liquid chromatography assay and related substances drug product method is provided. The benefits of applying QbD principles to analytical methods include identifying and minimizing sources of variability that may lead to poor method robustness and ensuring that the method meets its intended performance requirements throughout the product and method lifecycle.

Introduction Figure 1. ShahNov2009.pdf. Pharmaceutical “Quality by Design” (QbD): An Introduction, Process Development and Applications. Quality means fitness for intended use.

Pharmaceutical “Quality by Design” (QbD): An Introduction, Process Development and Applications

Pharmaceutical quality refers to product free of contamination and reproducibly delivers the therapeutic benefit promised in the label to the consumer. FCS4_1010_John_Berridge.pdf. UCM304305.pdf. Quality by Design : Design Space. Overview of pharmaceutical excipients used in tablets and capsules. The pharmaceutical industry is ever thirsty to satisfy patient’s therapeutical needs and apart from active ingredients, inactive excipients play a major role in formulation development.

Overview of pharmaceutical excipients used in tablets and capsules

Pharmaceutical excipients are substances other than the pharmacologically active drug or prodrug which are included in the manufacturing process or are contained in a finished pharmaceutical product dosage form. In addition to transporting the active drug to the site in the body where the drug is intended to exert its action, excipients play an important part in the manufacturing process. They may also be important for keeping the drug from being released too early in the assimilation process in places where it could damage tender tissue and create gastric irritation or stomach upset. Others help the drug to disintegrate into particles small enough to reach the blood stream more quickly and still others protect the product's stability so it will be at maximum effectiveness at time of use.

Rutesh H. 12F.pdf. International Society for Pharmaceutical Engineering. European Medicines Agency publishes booklet on European regulatory system for medicines. Promoting pharmaceutical science. Insight into New Drug Approvals in ICH Countries 2004-2013. The Centre for Innovation in Regulatory Science – CIRS recently published R&D Briefing 54, which looks specifically at trends in the number of New Active Substance (NAS) approval numbers and approval times across the following agencies’ processes: European Centralised, US FDA and Japananese PMDA.

Insight into New Drug Approvals in ICH Countries 2004-2013

Approvals are often a measure of the pharmaceutical industry’s output and are, along with approval times, used as markers of the regulatory environment. Principles and Practice of Drug Development. The Pharmaceutical Collection. Novartis. Ocw.uci.edu/cat/oo/getPage.php?course=OC0706041&lesson=1&topic=1&page=1. Protein Lounge - Biology Animations, Scientific Animations. Www.webcampus.stevens.edu/uploadedFiles/020_Degree_Programs/_pdf/PME530_Syllabus.pdf. Revolutionising Biomedical Education. How It's Made Pills. Www.abpischools.org.uk/res/coResourceImport/resources04/manufacturing/index.cfm. Pharmaceutical Institute - Understanding Pharma™ - Drug Development.